Cargando…

Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast Cancer

BACKGROUND: Intra-operative molecular diagnostic assays are currently used for the detection of lymph node metastases. The objective of this study was to find new biomarkers to improve diagnostic accuracy in the detection of metastatic axillary lymph nodes in breast cancer patients. METHODS: We appl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakaeean, Behnaz, Gholamin, Mehran, Tabatabaee Yazdi, Seyed Abbas, Forghani, Mohammad Naser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pasteur Institute of Iran 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275625/
https://www.ncbi.nlm.nih.gov/pubmed/31983196
http://dx.doi.org/10.29252/ibj.24.3.183
_version_ 1783542825349021696
author Bakaeean, Behnaz
Gholamin, Mehran
Tabatabaee Yazdi, Seyed Abbas
Forghani, Mohammad Naser
author_facet Bakaeean, Behnaz
Gholamin, Mehran
Tabatabaee Yazdi, Seyed Abbas
Forghani, Mohammad Naser
author_sort Bakaeean, Behnaz
collection PubMed
description BACKGROUND: Intra-operative molecular diagnostic assays are currently used for the detection of lymph node metastases. The objective of this study was to find new biomarkers to improve diagnostic accuracy in the detection of metastatic axillary lymph nodes in breast cancer patients. METHODS: We applied an absolute quantitative real-time RT-PCR to quantitate the expression of CK19, KLK11, and CLEC3A mRNAs in 79 FFPE SLNs from 35 breast cancer patients. The CK19 was confirmed as a standard biomarker, and the level of expression of selected new markers, KLK11 and CLEC3A, was evaluated in pathologically negative and positive SLNs by using absolute quantitative real-time PCR. RESULTS: The overall concordance of the CK19 gene with pathological results was 92.4% (less than 250 copies) in negative SLNs and 85% in positive SLNs (more than 250 copies). The sensitivity and specificity of CK19, which were detected by real-time PCR, was 85% and 46%, respectively. Our results revealed that lower CLEC3A was associated with more lymph node involvement. We could set a cut-off point for CLEC3A with the sensitivity of 78% and specificity of 60%. Also, the mean KLK11 had a statistically significant reverse correlation with tumor grade (p = 0.017). Higher CK19 levels were related to more tumor invasion (p < 0.0001). CONCLUSION: Regarding the findings, CLEC3A along with CK19 can be used as a promising marker with high sensitivity and specificity for the detection of metastatic SLN.
format Online
Article
Text
id pubmed-7275625
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Pasteur Institute of Iran
record_format MEDLINE/PubMed
spelling pubmed-72756252020-06-15 Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast Cancer Bakaeean, Behnaz Gholamin, Mehran Tabatabaee Yazdi, Seyed Abbas Forghani, Mohammad Naser Iran Biomed J Full Length BACKGROUND: Intra-operative molecular diagnostic assays are currently used for the detection of lymph node metastases. The objective of this study was to find new biomarkers to improve diagnostic accuracy in the detection of metastatic axillary lymph nodes in breast cancer patients. METHODS: We applied an absolute quantitative real-time RT-PCR to quantitate the expression of CK19, KLK11, and CLEC3A mRNAs in 79 FFPE SLNs from 35 breast cancer patients. The CK19 was confirmed as a standard biomarker, and the level of expression of selected new markers, KLK11 and CLEC3A, was evaluated in pathologically negative and positive SLNs by using absolute quantitative real-time PCR. RESULTS: The overall concordance of the CK19 gene with pathological results was 92.4% (less than 250 copies) in negative SLNs and 85% in positive SLNs (more than 250 copies). The sensitivity and specificity of CK19, which were detected by real-time PCR, was 85% and 46%, respectively. Our results revealed that lower CLEC3A was associated with more lymph node involvement. We could set a cut-off point for CLEC3A with the sensitivity of 78% and specificity of 60%. Also, the mean KLK11 had a statistically significant reverse correlation with tumor grade (p = 0.017). Higher CK19 levels were related to more tumor invasion (p < 0.0001). CONCLUSION: Regarding the findings, CLEC3A along with CK19 can be used as a promising marker with high sensitivity and specificity for the detection of metastatic SLN. Pasteur Institute of Iran 2020-05 2020-01-26 /pmc/articles/PMC7275625/ /pubmed/31983196 http://dx.doi.org/10.29252/ibj.24.3.183 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Full Length
Bakaeean, Behnaz
Gholamin, Mehran
Tabatabaee Yazdi, Seyed Abbas
Forghani, Mohammad Naser
Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast Cancer
title Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast Cancer
title_full Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast Cancer
title_fullStr Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast Cancer
title_full_unstemmed Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast Cancer
title_short Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast Cancer
title_sort novel biomarkers aim at detecting metastatic sentinel lymph nodes in breast cancer
topic Full Length
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275625/
https://www.ncbi.nlm.nih.gov/pubmed/31983196
http://dx.doi.org/10.29252/ibj.24.3.183
work_keys_str_mv AT bakaeeanbehnaz novelbiomarkersaimatdetectingmetastaticsentinellymphnodesinbreastcancer
AT gholaminmehran novelbiomarkersaimatdetectingmetastaticsentinellymphnodesinbreastcancer
AT tabatabaeeyazdiseyedabbas novelbiomarkersaimatdetectingmetastaticsentinellymphnodesinbreastcancer
AT forghanimohammadnaser novelbiomarkersaimatdetectingmetastaticsentinellymphnodesinbreastcancer